Eli Lilly and Company
LLY
$340.50
-$1.60-0.47%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 6.94B | 6.49B | 7.81B | 8.00B | 6.77B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.94B | 6.49B | 7.81B | 8.00B | 6.77B |
| Cost of Revenue | 1.58B | 1.43B | 2.07B | 2.15B | 1.43B |
| Gross Profit | 5.36B | 5.06B | 5.74B | 5.85B | 5.34B |
| SG&A Expenses | 1.52B | 1.53B | 1.46B | 1.52B | 1.51B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.90B | 4.74B | 5.15B | 5.62B | 4.64B |
| Operating Income | 2.04B | 1.74B | 2.66B | 2.38B | 2.13B |
| Income Before Tax | 1.57B | 1.09B | 2.05B | 1.84B | 1.25B |
| Income Tax Expenses | 113.80M | 138.40M | 150.70M | 113.80M | 135.20M |
| Earnings from Continuing Operations | 1.45B | 952.50M | 1.90B | 1.73B | 1.11B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.45B | 952.50M | 1.90B | 1.73B | 1.11B |
| EBIT | 2.04B | 1.74B | 2.66B | 2.38B | 2.13B |
| EBITDA | 2.40B | 2.09B | 3.10B | 2.82B | 2.51B |
| EPS Basic | 1.61 | 1.06 | 2.11 | 1.90 | 1.22 |
| Normalized Basic EPS | 1.36 | 1.15 | 1.83 | 1.36 | 1.43 |
| EPS Diluted | 1.61 | 1.05 | 2.10 | 1.89 | 1.22 |
| Normalized Diluted EPS | 1.35 | 1.14 | 1.82 | 1.36 | 1.42 |
| Average Basic Shares Outstanding | 900.70M | 900.30M | 903.70M | 909.56M | 906.70M |
| Average Diluted Shares Outstanding | 903.80M | 902.90M | 906.40M | 909.56M | 910.80M |
| Dividend Per Share | 0.98 | 0.98 | 0.98 | 0.85 | 0.85 |
| Payout Ratio | 60.77% | 92.78% | 46.53% | 44.80% | 69.40% |
